Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorKarci, Ebru
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBayram, Buket
dc.contributor.authorCelayir, Melisa
dc.contributor.authorOzyurt, Neslihan
dc.contributor.authorUluc, Basak Oyan
dc.contributor.authorEken, Aynur
dc.contributor.authorBasaran, Gul
dc.contributor.authorDemirci, Umut
dc.contributor.authorKemal, Yasemin
dc.contributor.authorOruncu, Mehmet Berk
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorErturk, Ismail
dc.contributor.authorBilgetekin, Irem
dc.contributor.authorCelik, Serkan
dc.contributor.authorTurkel, Alper
dc.contributor.authorAlkan, Ali
dc.contributor.authorSakin, Abdullah
dc.contributor.authorCan, Orcun
dc.contributor.authorGunaldi, Meral
dc.contributor.authorEsin, Ece
dc.contributor.authorYildiz, Ozcan
dc.date.accessioned2025-10-16T15:12:39Z
dc.date.issued2024
dc.identifier.doi10.3390/cancers16193389
dc.identifier.otherWOS:001331766600001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5547
dc.publisherMDPI
dc.sourceCANCERS
dc.subjecttriple\\-negative breast cancer
dc.subjectneoadjuvant therapy
dc.subjectpembrolizumab
dc.subjectpathological complete response
dc.subjectreal world
dc.subjectevent\\-free survival
dc.subjectoverall survival
dc.subjectsafety
dc.titleNeoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS